The glucocorticoid derivative with the phthalimide group cationic nanocrystal for ophthalmic application: a design space development approach

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorInstitute for Technological Research (IPT)-
Autor(es): dc.creatorPeters, M. C.C.-
Autor(es): dc.creatorde Oliveira, I. F.-
Autor(es): dc.creatorMachado, M. G.M. [UNESP]-
Autor(es): dc.creatorFerreira, D. C.-
Autor(es): dc.creatorZanin, M. H.A.-
Autor(es): dc.creatorBou-Chacra, N.-
Data de aceite: dc.date.accessioned2022-02-22T00:44:51Z-
Data de disponibilização: dc.date.available2022-02-22T00:44:51Z-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-03-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.mtchem.2020.100396-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/205628-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/205628-
Descrição: dc.descriptionThe glucocorticoid derivative of budesonide with a phthalimide group is a drug candidate to treat inflammatory eye diseases; nevertheless, it presents low water solubility. Drug nanocrystals have been proposed to overcome this hurdle. The development of an innovative ophthalmic anti-inflammatory nanosuspension was performed using a design space approach. We obtained the particle size reduction of this glucocorticoid derivative on a nanometer scale (approximately 165.0 nm), applying wet bead milling on a super reduced scale. The design of experiment supported the optimization of the formula evaluating the parameters that influence reducing the particle size and also allowed determining the design space. Considering the two statistical models developed and the size range obtained, we proposed that the optimized formulation for the glucocorticoid derivative nanosuspension may be 1.0 wt% glucocorticoid derivative and 0.092 wt% cetylpyridinium chloride. This formulation was characterized by the morphological, physical–chemical, and mucoadhesive in vitro test and showed potential for ophthalmic use with reduced frequency of product application, improved efficiency, and safety, which may promote better patient compliance.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionFaculty of Pharmaceutical Sciences Department of Pharmacy University of Sao Paulo, Avenida Professor Lineu Prestes 508, Butantan-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences São Paulo State University (UNESP), Rodovia Araraquara- Jaú Km 1, S/n, Campus Ville-
Descrição: dc.descriptionInstitute for Technological Research (IPT), Avenida Prof. Almeida Prado, 532, Butantã-
Descrição: dc.descriptionSchool of Pharmaceutical Sciences São Paulo State University (UNESP), Rodovia Araraquara- Jaú Km 1, S/n, Campus Ville-
Idioma: dc.languageen-
Relação: dc.relationMaterials Today Chemistry-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectBudesonide-
Palavras-chave: dc.subjectMucoadhesiveness-
Palavras-chave: dc.subjectNanosuspension-
Palavras-chave: dc.subjectOphthalmic therapy-
Palavras-chave: dc.subjectWet bead milling-
Título: dc.titleThe glucocorticoid derivative with the phthalimide group cationic nanocrystal for ophthalmic application: a design space development approach-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.